FDA Panel Supports Expanded Indications For Medtronic CRT-D Devices
This article was originally published in The Gray Sheet
Despite data concerns, FDA’s Circulatory System Devices advisory panel favors expanding the indications for Medtronic cardiac resynchronization therapy-defibrillator devices to allow treatment of heart failure patients with milder symptoms.
You may also be interested in...
The latest product approvals and launches in cardiology, ophthalmology and more.
Boston Scientific hopes its newfound ability to legally market its cardiac resynchronization therapy defibrillators for use in a broader heart failure population will help its efforts to regain lost market share in the sector
Boston Scientific's cardiac resynchronization therapy defibrillators (CRT-Ds) should be approved for use in some healthier heart failure patients, though not quite as many as the company initially proposed, an FDA advisory panel said March 18